This document provides an overview of endometriosis, including:
1. Definitions, symptoms, prevalence, risk factors, and theories of pathogenesis. Chronic inflammation plays a key role in the development and progression of endometriosis.
2. Diagnosis is based on clinical history and laparoscopic inspection with biopsy. Staging uses the ASRM or ENZIAN classification systems. Early diagnosis is important to mitigate symptoms and disease progression.
3. Endometriosis is associated with infertility due to factors like lesions, cysts, inflammation, and hormonal imbalances that create an adverse pelvic environment.
4. Medical therapy is essential as endometriosis cannot be cured,
Deck on current treatment approaches in endometriosis (PART II) Dr Jyoti AgAR...Lifecare Centre
Dydrogesterone is proposed as a new treatment for endometriosis. It effectively tackles chronic inflammation associated with endometriosis by reducing proinflammatory cytokines and increasing progesterone receptor expression. Clinical evidence shows that dydrogesterone provides symptomatic relief for endometriosis-related pain and improves quality of life. It also reduces the development of new endometriotic lesions and induces atrophy of ectopic endometrial tissue. Unlike other medications, dydrogesterone does not inhibit ovulation or require estrogen add-back therapy, and it may improve pregnancy outcomes for women with endometriosis.
Role of Dydrogesterone in Recurrent Pregnancy Loss Dr Sharda Jain Lifecare Centre
Dydrogesterone is commonly used by Indian gynecologists to treat recurrent pregnancy loss. It has higher bioavailability than natural micronized progesterone when taken orally. Dydrogesterone has an immunomodulatory effect that may help prevent miscarriage by inhibiting pro-inflammatory cytokines and increasing anti-inflammatory cytokines and progesterone-induced blocking factor production. It also increases uterine and endometrial blood flow by stimulating nitric oxide production. Several studies and meta-analyses indicate dydrogesterone may be more effective than natural micronized progesterone for treating recurrent pregnancy loss when taken orally, due to its higher bioavailability and specific affinity for progesterone receptors.
This document discusses progesterone and its role in female reproduction. It begins by explaining that fertility and menstruation are controlled by hormones, including estrogen and progesterone. Progesterone prepares the uterine lining for pregnancy and supports gestation. Dydrogesterone is then introduced as a synthetic progestogen used to treat gynecological disorders caused by low progesterone levels, such as premenstrual syndrome and recurrent miscarriage. Its mechanism of action, pharmacokinetics, indications, and dosage are described. Finally, a randomized controlled trial is summarized that found dydrogesterone to be as effective as micronized progesterone for luteal support during in vitro fertilization, with the benefit of oral versus vaginal administration.
Luteal phase support in ART Cases Dr Sharda Jain Lifecare Centre
The document discusses luteal phase support in assisted reproductive technology (ART) cycles. It provides 3 key points:
1. Luteal phase deficiency is common in ART cycles due to multiple factors like multifollicular development and aspiration of granulosa cells, leading to premature luteolysis and defective progesterone secretion.
2. Progesterone supplementation is important for luteal phase support as progesterone prepares the endometrium, decreases uterine contractility, and regulates immunity - all of which are important for embryo implantation and maintenance of early pregnancy.
3. Oral dydrogesterone is recommended for luteal phase support in ART cycles due to its greater bioavailability allowing the use of lower doses, minimal side effects
Role of Dydrogesterone in Threatened Abortion Dr Sharda Jain Lifecare Centre
*EXPERINCE SHARING By EXPERTS*
Dr Uma Rai(DGF *E*)
Dr Sangeetaa Gupta(DGF *E*)
Dr Neerja Varshney(DGF *E*)
Dr Surjeet Kapoor(DGF *E*)
Dr Rupam arora(DGF *E*)
Dr Meenakshi Ahuja(DGF *S* )
Dr.Harsha khullar(DGF *C* )
Dr Mamta mittal(DGF *N*)
Dr Leena Sreedhar(DGF *D*)
Dr.Dipti Nabh(DGF *E*)
Dr. Shama Batra(DGF *E*)
Dr Poonam Paul(DGF *SW*)
PAN DGF ( DELHI GYNAECOLOGIST FORUM) CME ON DYDROGESTERONE ON 3/2 /22
Recurrent pregnancy losses managing the unexplainedravikantraj55
This document discusses recurrent pregnancy losses and managing unexplained causes. It begins with an introduction to Dr. Manju Gita Mishra who has extensive experience in obstetrics and gynecology. The document then covers definitions of recurrent pregnancy loss, common causes, diagnostic evaluation, and treatment options including progesterone supplementation which some studies have found reduces subsequent miscarriage rates in women with unexplained recurrent miscarriages. It discusses challenges in identifying the cause in about 50% of recurrent pregnancy loss cases and stratifying women into those whose losses are likely due to chance versus an underlying abnormality.
Deck on current treatment approaches in endometriosis (PART II) Dr Jyoti AgAR...Lifecare Centre
Dydrogesterone is proposed as a new treatment for endometriosis. It effectively tackles chronic inflammation associated with endometriosis by reducing proinflammatory cytokines and increasing progesterone receptor expression. Clinical evidence shows that dydrogesterone provides symptomatic relief for endometriosis-related pain and improves quality of life. It also reduces the development of new endometriotic lesions and induces atrophy of ectopic endometrial tissue. Unlike other medications, dydrogesterone does not inhibit ovulation or require estrogen add-back therapy, and it may improve pregnancy outcomes for women with endometriosis.
Role of Dydrogesterone in Recurrent Pregnancy Loss Dr Sharda Jain Lifecare Centre
Dydrogesterone is commonly used by Indian gynecologists to treat recurrent pregnancy loss. It has higher bioavailability than natural micronized progesterone when taken orally. Dydrogesterone has an immunomodulatory effect that may help prevent miscarriage by inhibiting pro-inflammatory cytokines and increasing anti-inflammatory cytokines and progesterone-induced blocking factor production. It also increases uterine and endometrial blood flow by stimulating nitric oxide production. Several studies and meta-analyses indicate dydrogesterone may be more effective than natural micronized progesterone for treating recurrent pregnancy loss when taken orally, due to its higher bioavailability and specific affinity for progesterone receptors.
This document discusses progesterone and its role in female reproduction. It begins by explaining that fertility and menstruation are controlled by hormones, including estrogen and progesterone. Progesterone prepares the uterine lining for pregnancy and supports gestation. Dydrogesterone is then introduced as a synthetic progestogen used to treat gynecological disorders caused by low progesterone levels, such as premenstrual syndrome and recurrent miscarriage. Its mechanism of action, pharmacokinetics, indications, and dosage are described. Finally, a randomized controlled trial is summarized that found dydrogesterone to be as effective as micronized progesterone for luteal support during in vitro fertilization, with the benefit of oral versus vaginal administration.
Luteal phase support in ART Cases Dr Sharda Jain Lifecare Centre
The document discusses luteal phase support in assisted reproductive technology (ART) cycles. It provides 3 key points:
1. Luteal phase deficiency is common in ART cycles due to multiple factors like multifollicular development and aspiration of granulosa cells, leading to premature luteolysis and defective progesterone secretion.
2. Progesterone supplementation is important for luteal phase support as progesterone prepares the endometrium, decreases uterine contractility, and regulates immunity - all of which are important for embryo implantation and maintenance of early pregnancy.
3. Oral dydrogesterone is recommended for luteal phase support in ART cycles due to its greater bioavailability allowing the use of lower doses, minimal side effects
Role of Dydrogesterone in Threatened Abortion Dr Sharda Jain Lifecare Centre
*EXPERINCE SHARING By EXPERTS*
Dr Uma Rai(DGF *E*)
Dr Sangeetaa Gupta(DGF *E*)
Dr Neerja Varshney(DGF *E*)
Dr Surjeet Kapoor(DGF *E*)
Dr Rupam arora(DGF *E*)
Dr Meenakshi Ahuja(DGF *S* )
Dr.Harsha khullar(DGF *C* )
Dr Mamta mittal(DGF *N*)
Dr Leena Sreedhar(DGF *D*)
Dr.Dipti Nabh(DGF *E*)
Dr. Shama Batra(DGF *E*)
Dr Poonam Paul(DGF *SW*)
PAN DGF ( DELHI GYNAECOLOGIST FORUM) CME ON DYDROGESTERONE ON 3/2 /22
Recurrent pregnancy losses managing the unexplainedravikantraj55
This document discusses recurrent pregnancy losses and managing unexplained causes. It begins with an introduction to Dr. Manju Gita Mishra who has extensive experience in obstetrics and gynecology. The document then covers definitions of recurrent pregnancy loss, common causes, diagnostic evaluation, and treatment options including progesterone supplementation which some studies have found reduces subsequent miscarriage rates in women with unexplained recurrent miscarriages. It discusses challenges in identifying the cause in about 50% of recurrent pregnancy loss cases and stratifying women into those whose losses are likely due to chance versus an underlying abnormality.
Role of Dydrogesterone in repeated pregnancy lossNiranjan Chavan
Dydrogesterone has been shown to effectively treat recurrent pregnancy loss by modulating the immune system. It shifts the balance from a pro-inflammatory Th1 response towards an anti-inflammatory Th2 response by [1] inhibiting the production of Th1 cytokines IFN-γ and TNF-α and [2] inducing production of the Th2 cytokines IL-4 and IL-6. This results in improved pregnancy outcomes by supporting embryonic development. Clinical studies demonstrate dydrogesterone significantly reduces miscarriage rates in women with recurrent pregnancy loss.
Role of progestogens in obstetrics and gynecologyAhmad Saber
The
different progestogens with their overlapping effects on estrogen, androgen, glucocorticoid,
and mineralocorticoid receptors are described in order to allow the clinician to make the most appropriate choice of progestogen.
This document provides information on progestins and their use in treating endometriosis. It focuses on dienogest, a new hybrid progestin. It discusses dienogest's pharmacological properties, advantages over other treatments like GnRH agonists, and clinical trial results showing its efficacy and safety. Long-term use of up to 52 weeks is shown to control symptoms with minimal side effects. Dienogest also allows for prompt return of fertility and ovulation after treatment.
Dydrogesterone is a progestin hormone used to regulate the healthy growth and shedding of the womb lining. It was first introduced in 1961 and is now approved in over 100 countries. It works by selectively binding to progesterone receptors and has an active metabolite called 20α-dihydrodydrogesterone that is non-sedative. Dydrogesterone is used orally at doses of 5-40 mg daily or via intramuscular injection of 100 mg daily to treat menstrual disorders, prevent miscarriage, treat endometriosis, support fertility, and prevent thickening of the uterine lining during hormone replacement therapy. Common side effects include headaches, breast pain or tenderness, spotting, and changes to menstrual periods
Dienogest+ Ethinyl Estradiol Role in oral contraception & Acne Dr Sharda Jain...Lifecare Centre
Dienogest + Ethinyl Estradiol is a combination oral contraceptive pill that provides contraception and treats mild to moderate acne. It contains the 4th generation progestin Dienogest and the estrogen Ethinyl Estradiol. Dienogest has anti-androgenic properties and does not have the side effects seen with other progestins like weight gain, acne, or changes in lipids. It works primarily by suppressing gonadotropins to inhibit ovulation and by changing cervical mucus to block sperm entry. Clinical trials demonstrate it is effective contraception with fewer side effects than other pills.
It describes the Progesterone physiology. It describes the latest evidence as regards progesterone formulations, use of progesterone as Luteal phase support. It scrutinizes the value of serum progesterone in monitoring luteal phase
Newer concepts of managing PCOD With Myo-InositolLifecare Centre
Myo-inositol is an effective treatment for polycystic ovary syndrome (PCOS) that works by improving insulin sensitivity and reducing androgen levels. Clinical studies show that myo-inositol reduces testosterone and fasting insulin levels, improves menstrual regularity and ovulation rates, and can help induce pregnancy in women with PCOS. Myo-inositol is a safe and well-tolerated treatment for PCOS that provides metabolic, reproductive, and dermatological benefits without major side effects.
Threatened Miscarriage Verdict is out on Hormonal Treatment Dr Jyoti AgarwalLifecare Centre
- Threatened miscarriage occurs in around 15% of clinically recognized pregnancies and can cause significant emotional and psychological stress for couples.
- Multiple meta-analyses and randomized controlled trials have found that oral administration of dydrogesterone is more effective at reducing the risk of miscarriage in cases of threatened miscarriage compared to vaginal progesterone or no treatment.
- Dydrogesterone has higher bioavailability when taken orally compared to micronized progesterone, requires a lower dose, and may have immunomodulatory properties that further reduce the risk of miscarriage.
This document summarizes evidence on the use of progesterone to prevent preterm birth. It finds that progesterone reduces the risk of preterm birth before 37 weeks in women with a prior preterm delivery or short cervix. Progesterone may also reduce complications for infants born preterm to mothers receiving it. However, progesterone does not prevent early preterm birth in twin or triplet pregnancies. No long-term harms were seen in children exposed to progesterone prenatally.
What is 40 : 1 In management of Dr. Jyoti Agarwal Dr. Sharda Jain Dr. Jyo...Lifecare Centre
The document discusses polycystic ovarian syndrome (PCOS) and the role of insulin resistance and inositols (myo-inositol and D-chiro inositol) in its pathophysiology and treatment. Women with PCOS have lower levels and higher clearance of inositols. Supplementation with myo-inositol and D-chiro inositol in a 40:1 ratio has been shown to improve hormonal and metabolic abnormalities in PCOS by addressing insulin resistance and restoring normal cellular processes and ovarian function. Combined therapy of myo-inositol and D-chiro inositol in a physiological ratio may be a first-line approach for overweight women with PCOS
Progesterone, new values in clinical practiceMamdouh Sabry
- Progesterone is a steroid hormone that plays several important roles in the female reproductive system and pregnancy. It can be produced naturally in the body or taken as a synthetic progestin medication.
- There are two major progesterone receptor subtypes, PRA and PRB. PRA inhibits the effects of PRB and other steroid receptors in many tissues where they are expressed.
- Micronized natural progesterone from plant sources has fewer side effects than older synthetic progestins and more closely mimics the body's endogenous progesterone. It can be administered orally, vaginally, or through other routes.
- Progesterone supplementation shows benefits for preventing preterm birth and recurrent pregnancy loss according to some studies,
Since the first formal description of LPD in 1949 as a possible cause of infertility and recurrent miscarriage by Jones. Innumerable investigations have been undertaken in an effort to verify its existence or to characterize its pathophysiology, diagnosis, and treatment. The consensus of the literature is that LPD does exist and that its cause is multifactorial like abnormal folliculogenesis, inadequate LH surge,inadequate secretion of progesterone by the corpus luteum, aberrant end-organ response by the endometrium.
This seminar explores the potential connection between two inositol stereoisomers supplements and improvements in insulin sensitivity and various metabolic parameters.
Dydrogesterone has higher bioavailability (up to 28%) compared to micronized progesterone (less than 10%), allowing it to be effective at a much lower dose of 10-30 mg/day versus 200-300 mg/day for micronized progesterone. Dydrogesterone also causes fewer adverse effects due to its minimal activation of non-progesterone receptors. While dydrogesterone has extensive clinical trial evidence and approvals for threatened miscarriage and progesterone deficiencies, micronized progesterone only has trials and approval for secondary amenorrhea.
1) Luteal phase support is important for assisted reproduction cycles to ensure adequate progesterone levels and proper endometrial development.
2) Progesterone supplementation is generally recommended, with micronized progesterone or dydrogesterone being good options. Vaginal administration is equally effective as intramuscular with fewer side effects.
3) Progesterone should be started 24-48 hours after egg retrieval/release and continued until 9 weeks of pregnancy. The addition of a single GnRH agonist dose may further improve outcomes. hCG is not recommended due to risk of OHSS.
Oxidative Stress is a major contributor of unexplained female infertility and male factor infertility.Recent Cochrane database metanalysis suggests there is a low but significant improvement in fertility with use of various micronutrients and antioxidant supplements.
Menopausal hormone therapy (MHT) also called postmenopausal hormone therapy and hormone replacement therapy. Here is presentation on Menopausal hormone therapy by Dr. Laxmi Shrikhande
MICRONUTRIENTS IN MALE INFERTILITY BY DR SHASHWAT JANIDR SHASHWAT JANI
This document discusses male infertility and the role of micronutrients. It begins by introducing Dr. Shashwat Jani and his credentials. It then summarizes several studies that show a relationship between micronutrient deficiencies and male infertility. Specifically, it discusses how reactive oxygen species (ROS) produced by inadequate antioxidant levels can damage sperm cells. The document provides examples of antioxidants like carnitine, coenzyme Q10, and lycopene that have been shown in clinical trials to improve semen quality parameters and fertility outcomes when supplemented.
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain Lifecare Centre
1. Dr. Sharda Jain is a renowned expert in infertility and IVF in India, holding leadership roles in several professional organizations related to gynecology and women's health.
2. She has received numerous awards and recognition for her contributions, including being included in a list of the top 20 most influential women in healthcare in India.
3. Her areas of focus and advocacy have included campaigns against female feticide and increasing access to healthcare for women.
we need to update our knowledge regarding management of endometriosis.
Which is better: medications or surgery? let's see what can this talk tell us about
This document discusses the many non-contraceptive benefits of combined oral contraceptives (COCP). It notes that 33% of adolescents using COCP do so for non-contraceptive reasons approved by research. COCP can effectively treat conditions like dysmenorrhea, dysmenorrhea, signs of androgenization, PMS, ovarian cysts, endometriosis, adenomyosis, myoma, and others. It discusses the mechanisms by which COCP provides these benefits and provides evidence from multiple studies. The document emphasizes that understanding these non-contraceptive benefits can enhance healthcare providers' care of patients.
Role of Dydrogesterone in repeated pregnancy lossNiranjan Chavan
Dydrogesterone has been shown to effectively treat recurrent pregnancy loss by modulating the immune system. It shifts the balance from a pro-inflammatory Th1 response towards an anti-inflammatory Th2 response by [1] inhibiting the production of Th1 cytokines IFN-γ and TNF-α and [2] inducing production of the Th2 cytokines IL-4 and IL-6. This results in improved pregnancy outcomes by supporting embryonic development. Clinical studies demonstrate dydrogesterone significantly reduces miscarriage rates in women with recurrent pregnancy loss.
Role of progestogens in obstetrics and gynecologyAhmad Saber
The
different progestogens with their overlapping effects on estrogen, androgen, glucocorticoid,
and mineralocorticoid receptors are described in order to allow the clinician to make the most appropriate choice of progestogen.
This document provides information on progestins and their use in treating endometriosis. It focuses on dienogest, a new hybrid progestin. It discusses dienogest's pharmacological properties, advantages over other treatments like GnRH agonists, and clinical trial results showing its efficacy and safety. Long-term use of up to 52 weeks is shown to control symptoms with minimal side effects. Dienogest also allows for prompt return of fertility and ovulation after treatment.
Dydrogesterone is a progestin hormone used to regulate the healthy growth and shedding of the womb lining. It was first introduced in 1961 and is now approved in over 100 countries. It works by selectively binding to progesterone receptors and has an active metabolite called 20α-dihydrodydrogesterone that is non-sedative. Dydrogesterone is used orally at doses of 5-40 mg daily or via intramuscular injection of 100 mg daily to treat menstrual disorders, prevent miscarriage, treat endometriosis, support fertility, and prevent thickening of the uterine lining during hormone replacement therapy. Common side effects include headaches, breast pain or tenderness, spotting, and changes to menstrual periods
Dienogest+ Ethinyl Estradiol Role in oral contraception & Acne Dr Sharda Jain...Lifecare Centre
Dienogest + Ethinyl Estradiol is a combination oral contraceptive pill that provides contraception and treats mild to moderate acne. It contains the 4th generation progestin Dienogest and the estrogen Ethinyl Estradiol. Dienogest has anti-androgenic properties and does not have the side effects seen with other progestins like weight gain, acne, or changes in lipids. It works primarily by suppressing gonadotropins to inhibit ovulation and by changing cervical mucus to block sperm entry. Clinical trials demonstrate it is effective contraception with fewer side effects than other pills.
It describes the Progesterone physiology. It describes the latest evidence as regards progesterone formulations, use of progesterone as Luteal phase support. It scrutinizes the value of serum progesterone in monitoring luteal phase
Newer concepts of managing PCOD With Myo-InositolLifecare Centre
Myo-inositol is an effective treatment for polycystic ovary syndrome (PCOS) that works by improving insulin sensitivity and reducing androgen levels. Clinical studies show that myo-inositol reduces testosterone and fasting insulin levels, improves menstrual regularity and ovulation rates, and can help induce pregnancy in women with PCOS. Myo-inositol is a safe and well-tolerated treatment for PCOS that provides metabolic, reproductive, and dermatological benefits without major side effects.
Threatened Miscarriage Verdict is out on Hormonal Treatment Dr Jyoti AgarwalLifecare Centre
- Threatened miscarriage occurs in around 15% of clinically recognized pregnancies and can cause significant emotional and psychological stress for couples.
- Multiple meta-analyses and randomized controlled trials have found that oral administration of dydrogesterone is more effective at reducing the risk of miscarriage in cases of threatened miscarriage compared to vaginal progesterone or no treatment.
- Dydrogesterone has higher bioavailability when taken orally compared to micronized progesterone, requires a lower dose, and may have immunomodulatory properties that further reduce the risk of miscarriage.
This document summarizes evidence on the use of progesterone to prevent preterm birth. It finds that progesterone reduces the risk of preterm birth before 37 weeks in women with a prior preterm delivery or short cervix. Progesterone may also reduce complications for infants born preterm to mothers receiving it. However, progesterone does not prevent early preterm birth in twin or triplet pregnancies. No long-term harms were seen in children exposed to progesterone prenatally.
What is 40 : 1 In management of Dr. Jyoti Agarwal Dr. Sharda Jain Dr. Jyo...Lifecare Centre
The document discusses polycystic ovarian syndrome (PCOS) and the role of insulin resistance and inositols (myo-inositol and D-chiro inositol) in its pathophysiology and treatment. Women with PCOS have lower levels and higher clearance of inositols. Supplementation with myo-inositol and D-chiro inositol in a 40:1 ratio has been shown to improve hormonal and metabolic abnormalities in PCOS by addressing insulin resistance and restoring normal cellular processes and ovarian function. Combined therapy of myo-inositol and D-chiro inositol in a physiological ratio may be a first-line approach for overweight women with PCOS
Progesterone, new values in clinical practiceMamdouh Sabry
- Progesterone is a steroid hormone that plays several important roles in the female reproductive system and pregnancy. It can be produced naturally in the body or taken as a synthetic progestin medication.
- There are two major progesterone receptor subtypes, PRA and PRB. PRA inhibits the effects of PRB and other steroid receptors in many tissues where they are expressed.
- Micronized natural progesterone from plant sources has fewer side effects than older synthetic progestins and more closely mimics the body's endogenous progesterone. It can be administered orally, vaginally, or through other routes.
- Progesterone supplementation shows benefits for preventing preterm birth and recurrent pregnancy loss according to some studies,
Since the first formal description of LPD in 1949 as a possible cause of infertility and recurrent miscarriage by Jones. Innumerable investigations have been undertaken in an effort to verify its existence or to characterize its pathophysiology, diagnosis, and treatment. The consensus of the literature is that LPD does exist and that its cause is multifactorial like abnormal folliculogenesis, inadequate LH surge,inadequate secretion of progesterone by the corpus luteum, aberrant end-organ response by the endometrium.
This seminar explores the potential connection between two inositol stereoisomers supplements and improvements in insulin sensitivity and various metabolic parameters.
Dydrogesterone has higher bioavailability (up to 28%) compared to micronized progesterone (less than 10%), allowing it to be effective at a much lower dose of 10-30 mg/day versus 200-300 mg/day for micronized progesterone. Dydrogesterone also causes fewer adverse effects due to its minimal activation of non-progesterone receptors. While dydrogesterone has extensive clinical trial evidence and approvals for threatened miscarriage and progesterone deficiencies, micronized progesterone only has trials and approval for secondary amenorrhea.
1) Luteal phase support is important for assisted reproduction cycles to ensure adequate progesterone levels and proper endometrial development.
2) Progesterone supplementation is generally recommended, with micronized progesterone or dydrogesterone being good options. Vaginal administration is equally effective as intramuscular with fewer side effects.
3) Progesterone should be started 24-48 hours after egg retrieval/release and continued until 9 weeks of pregnancy. The addition of a single GnRH agonist dose may further improve outcomes. hCG is not recommended due to risk of OHSS.
Oxidative Stress is a major contributor of unexplained female infertility and male factor infertility.Recent Cochrane database metanalysis suggests there is a low but significant improvement in fertility with use of various micronutrients and antioxidant supplements.
Menopausal hormone therapy (MHT) also called postmenopausal hormone therapy and hormone replacement therapy. Here is presentation on Menopausal hormone therapy by Dr. Laxmi Shrikhande
MICRONUTRIENTS IN MALE INFERTILITY BY DR SHASHWAT JANIDR SHASHWAT JANI
This document discusses male infertility and the role of micronutrients. It begins by introducing Dr. Shashwat Jani and his credentials. It then summarizes several studies that show a relationship between micronutrient deficiencies and male infertility. Specifically, it discusses how reactive oxygen species (ROS) produced by inadequate antioxidant levels can damage sperm cells. The document provides examples of antioxidants like carnitine, coenzyme Q10, and lycopene that have been shown in clinical trials to improve semen quality parameters and fertility outcomes when supplemented.
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain Lifecare Centre
1. Dr. Sharda Jain is a renowned expert in infertility and IVF in India, holding leadership roles in several professional organizations related to gynecology and women's health.
2. She has received numerous awards and recognition for her contributions, including being included in a list of the top 20 most influential women in healthcare in India.
3. Her areas of focus and advocacy have included campaigns against female feticide and increasing access to healthcare for women.
we need to update our knowledge regarding management of endometriosis.
Which is better: medications or surgery? let's see what can this talk tell us about
This document discusses the many non-contraceptive benefits of combined oral contraceptives (COCP). It notes that 33% of adolescents using COCP do so for non-contraceptive reasons approved by research. COCP can effectively treat conditions like dysmenorrhea, dysmenorrhea, signs of androgenization, PMS, ovarian cysts, endometriosis, adenomyosis, myoma, and others. It discusses the mechanisms by which COCP provides these benefits and provides evidence from multiple studies. The document emphasizes that understanding these non-contraceptive benefits can enhance healthcare providers' care of patients.
Recent advances in endometriosis were discussed. Endometriosis is a chronic disease where endometrial tissue grows outside the uterus, affecting around 10% of women. Dienogest, a progestin, was shown to be effective in reducing endometriosis-associated pelvic pain in randomized controlled trials. Dienogest 2mg daily for 24 weeks provided pain relief similar to leuprolide acetate but with fewer side effects. Long-term use of dienogest for 65 weeks maintained pain relief with a favorable safety profile. Dienogest was as effective as goserelin in reducing postoperative recurrence of endometriosis at 24 months.
ENDOMETRIOSIS UPDATEFocus on Dienogest Dr Sharda jain dr Jyoti Agarwal Lifecare Centre
ENDOMETRIOSIS UPDATEFocus on Dienogest
AGENDA
Background
What’s New in Endometriosis
Clinical Discussions in Managing Endometriosis
Newer Evidences on Dienogest
The Newer Concepts In Endometriosis Management : Dr Sharda JainLifecare Centre
The Newer Concepts In
Endometriosis Management
ENDOMETRIOSIS IS ENIGMA
DIAGNOSTIC DELEMMA
DEBILITATING DISEASE QOL
PROGRESSIVE DISEASE
RECURRENCE IS BIG PROBLEM
NO FINAL VERDICT ON CAUSE
NO PERMANENT CURE
The exact prevalence of endometriosis is unknown, but estimates 10% in the general female population in India but up to 50% in infertile women
Diagnosis & Management of Endometriosis: pathophysilogy to practiceAzizan Hanny
This document provides information about a module on the diagnosis and management of endometriosis. It discusses the pathophysiology, symptoms, historical background, theories of pathogenesis, and diagnosis and treatment of endometriosis. The module includes an online monograph, PowerPoint slides, and interactive case studies to educate medical professionals on timely diagnosis and effective treatment of endometriosis to improve outcomes for patients.
Cabgolin in Endometriosis - Recent advances.pptxVidushRatan1
This document discusses endometriosis, a condition where endometrial-type mucosa grows outside the uterine cavity. It predominantly affects women during their reproductive years and is associated with pelvic pain and infertility. The exact prevalence is unknown due to reliance on surgical visualization for diagnosis. Current medical therapies include analgesics, hormonal therapies, and GnRH analogues which have side effects. Surgical treatments also carry risks. The document discusses the role of angiogenesis in the pathogenesis and survival of endometriotic lesions. Emerging evidence suggests estrogens can both promote and inhibit endometrial vessel growth. Anti-angiogenic treatments have shown success in experimental models by inhibiting new vessel formation. Dopamine agonists like cabergoline are
IOSRPHR(www.iosrphr.org) IOSR Journal of Pharmacyiosrphr_editor
The document summarizes a study on the efficacy and safety of vaginal misoprostol for second trimester medical termination of pregnancy. 148 women between 13-20 weeks gestation were given initial doses of 400 micrograms of misoprostol followed by 200 micrograms every 4 hours. The overall success rate was 92% with an average induction-abortion interval of 14 hours. Common side effects like cramping, nausea and diarrhea were reported but were managed with symptomatic treatment. The study concluded that misoprostol was found to be safe and effective for second trimester medical termination of pregnancy.
Presentazione a cura del Professor Franco Scaldaferri - M.A.S.T.E.R. ECM in Gastroenterologia: Approccio personalizzato alla complessità in Gastroenterologia - Fondazione Santa Lucia - Roma 19/01/2018
This document provides an overview of endometriosis from Dr. S.N. Sethi. Some key points:
- Endometriosis is often misdiagnosed, taking an average of 8 years to diagnose correctly.
- It is estrogen-dependent and invasive, with lesions found in various locations besides the uterus.
- Symptoms include pelvic pain and infertility. Dienogest is highlighted as an effective long-term medical treatment that provides pain relief and few side effects.
- Studies show Dienogest significantly reduces endometriosis lesions and symptoms compared to placebo and has similar efficacy to leuprolide with fewer side effects.
This document discusses inflammatory bowel disease (IBD) and its relevance to primary care clinicians. Key points include:
- IBD is common in the US, affecting hundreds of thousands annually with billions in costs. Delayed diagnosis can lead to worse outcomes.
- Primary care clinicians play an important role in initial recognition of IBD symptoms, ongoing health maintenance for IBD patients, and monitoring for complications from immunosuppressive therapies.
- Diagnosing IBD requires considering symptoms, labs, endoscopy, and radiography. Treatment goals include inducing remission and mucosal healing through a treat-to-target approach using medications like 5-ASAs, corticosteroids, immunomodulators,
Endometriosis & INDIA A comprehensive update : Dr Sharda Jain Lifecare Centre
The document provides an overview of endometriosis in India. It discusses the prevalence of endometriosis in India, with an estimated 26 million people affected. The peak age range is 25-35 years old. Common signs and symptoms include pelvic pain, dysmenorrhea, and infertility. Endometriosis is most commonly found in the pelvis and ovaries. Diagnosis is via laparoscopy, though some guidelines support empiric treatment first to address symptoms. The American Fertility Society staging system is used to classify endometriosis based on location, extent, and disease severity. Risk factors include lower birth weight, earlier age of menarche, and lower body mass index.
Hold oxygen mask
Monitor vital signs
IV fluids if needed
45 8/31/2012 Dr. Nitika Jain
46 Dr. nitika jain 31 August 2012
Local anesthetic and analgesic
administration during pregnancy
Local anesthetics are safe to use during pregnancy.
Lignocaine is the local anesthetic of choice during
pregnancy.
Use the minimum effective dose.
Avoid repeated administration of local anesthetics.
Use aspirin or acetaminophen for analgesia during
pregnancy.
Avoid NSAIDs during pregnancy
This document discusses the treatment of endometriosis using an integrated approach of Traditional Chinese Medicine (TCM) and Western Medicine (WM). It begins by providing background on endometriosis, including definitions, prevalence, causes, risk factors, clinical manifestations, diagnosis, and WM treatment options such as medical therapies and surgery. The document then states that TCM is an effective natural treatment for endometriosis while WM can surgically remove ectopic tissues, but integrating TCM and WM can greatly benefit treatment.
Menopausal Harmone Therapy & Indian Gynaecologists Dr Sharda Jain Lifecare Centre
This document discusses menopause and menopausal hormone therapy (MHT). It provides information on:
1) The average age of menopause for Indian women is 46.2 years. Premature menopause, which occurs before age 40, increases risks for cardiovascular disease, diabetes, and metabolic syndrome.
2) Lessons learned from the WHI study show that the risks of MHT depend on factors like age of starting treatment, type of estrogen and progestogen used, and whether the uterus is present. Not all progestogens have the same safety profile.
3) The choice of progestogen is important as some, like medroxyprogesterone acetate (MPA), may
Hot Topics In Integrative Medicine Jill Schneiderhan.pptxssuser1fae2b
This document summarizes a presentation on hot topics in integrative medicine, including chronic pain management, the microbiome, menopausal symptoms, mindfulness, elimination diets, and acupuncture. It reviews evidence for approaches like physical activity, anti-inflammatory diets, probiotics, and supplements for chronic pain, irritable bowel syndrome, obesity, and diabetes. Non-hormonal therapies for menopausal symptoms like CBT, yoga, and acupuncture are discussed. Mindfulness-based stress reduction and elimination diets are described as commonly used integrative therapies. The document concludes by listing resources for integrative medicine evidence.
Endometriomas (chocolate cysts) are associated with infertility in 17-44% of endometriosis cases. Sampson's theory of retrograde menstruation leading to implantation and growth of endometrial tissue is still widely accepted, but does not fully explain all cases of endometriosis. Factors like genetic predisposition, immunological and hormonal changes, oxidative stress, and environmental toxins likely all contribute to the initiation and maintenance of endometriosis. The disease and associated endometriomas can cause infertility through effects on the endometrium like dysregulation of genes important for embryo implantation, and increased inflammatory cytokines that are cytotoxic and disrupt the uterine environment.
Similar to Dydrogesterone का नया अवतार (Part 1) Dr Sharda Jain (20)
The Newer Concepts forReduced Surgery to preserve fertility in Endometrios...Lifecare Centre
The Newer Concepts forReduced Surgery to preserve fertility in Endometriosis
ENDOMETRIOSIS IS ENIGMA
DIAGNOSTIC DILEMMA
DEBILITATING DISEASE QOL
PROGRESSIVE DISEASE
RECURRENCE IS BIG PROBLEM
NO FINAL VERDICT ON CAUSE
NO PERMANENT CURE
The exact prevalence of endometriosis is unknown, but estimates 10% in the general female population in India but up to 50% in infertile women
Anemia Free India Gynaecologist to focuss on *12gm Haemoglobin at Delivery I...Lifecare Centre
Important Highlights
Prophylactic Iron and Folic Acid Supplementation in all six target age groups.
Intensified year-round Behaviour Change Communication (BCC) Campaign for:(a) improving compliance to IFA and deworming, (b) enhancing appropriate infant and young child feeding practices, (c) encouraging increase in intake of iron-rich food through diet and/or fortified foods (d) ensuring delayed cord clamping .
Testing and treatment of anaemia, using digital methods and point of care treatment, with special focus on pregnant women and school-going adolescents.
Addressing non-nutritional causes of anaemia
in endemic pockets with special focus on malaria, hemoglobinopathies and fluorosis
Liver Dialogue for Gynaecologists : Dr Sharda JainLifecare Centre
This document discusses the functions of the liver and various liver function tests. It notes that the liver has important metabolic, excretory, protective, hematological, synthetic and storage functions. It then describes several common liver function tests including SGPT, SGOT, GGT, ALP, bilirubin, total protein, albumin, PT, bleeding time and clotting time. It provides details on the clinical significance, normal ranges and potential causes of interference for each of these tests. The document emphasizes that liver function tests can help screen for and diagnose liver dysfunction, assess prognosis, and monitor response to therapy.
National Tuberculosis elimination programme (NIKSHAY)Big Challenge to GOI : ...Lifecare Centre
India has a high tuberculosis (TB) burden, accounting for approximately 50% of global cases. The Government of India's National Tuberculosis Elimination Program (NTEP) aims to eliminate TB in India by 2025 through programs like NIKSHAY and NIKSHAY MITRA SCHEME. However, India faces significant challenges to eliminating TB, including delays in diagnosis, drug-resistant strains, poor treatment adherence, stigma, comorbidity with HIV/AIDS, weaknesses in healthcare infrastructure, and social determinants like poverty and overcrowding. Overcoming these challenges will require sustained political will, funding, and strengthened surveillance and monitoring systems.
This document discusses innovations and breakthroughs in in vitro fertilization (IVF). It covers the following topics in 3 sentences or less:
Genetic screening techniques like preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) are discussed to select embryos without genetic disorders or the highest chance of implantation. Time-lapse monitoring is presented as a way to continuously monitor embryo development in real-time without disruptions. Stem cell therapy and its potential role in inducing ovarian regeneration and sustained ovarian function is briefly covered.
Strategies for Improving Success Rates in ART PARTLifecare Centre
Strategies for Improving Success Rates in ART
Part - 2
Strategies for Improving Success Rates in ART
Tailoring Controlled Ovarian Stimulation
Strategies for Luteal Phase in ART cycles
Endometrial Receptivity Array
20 Simple ways for the Indian public to save water on World Water Day : Dr Sh...Lifecare Centre
Simple ways for the Indian public to save water on World Water Day include fixing leaks, installing faucet aerators to reduce water flow, and taking shorter showers. Other tips are to turn off taps when not in use, collect rainwater, and reuse greywater from washing for gardening. People should also use buckets instead of hoses for tasks like washing vehicles and water plants wisely to minimize evaporation.
Vaccination during Pregnancy & its Importance : Dr Sharda JainLifecare Centre
This document discusses the importance of vaccination during pregnancy. Some key points:
- Global and national health authorities recommend vaccines for influenza, tetanus, diphtheria, and pertussis during pregnancy to protect both mother and baby. Maternal immunization provides passive immunity to newborns.
- Pregnant women and young infants are especially vulnerable to certain infections. Vaccination of mothers during pregnancy is the most effective strategy to protect newborns who are too young for certain vaccines.
- Clinical trials have shown vaccines such as the Tdap and influenza vaccines to be generally safe and effective for pregnant women and their infants. Maternal immunization has significantly reduced disease in newborns for illnesses like
How to optimize success rates in ART? : Dr Sharda JainLifecare Centre
How to optimize success rates in ART? : Dr Sharda Jain
How to improve success rates in ART?
The big debate कार्य में आनंद
Evolution of In-vitro Fertilization (IVF)
Factors Influencing IVF Success Ist Part
Strategies for Improving Success Rates in ART Second Part
Innovations & Breakthroughs in IVF Part Three
OPEN DEBATE
SOCIALEGG FREEZING : Dr Poorva Bhargav and Dr Sharda JainLifecare Centre
SOCIALEGG FREEZING : Dr Poorva Bhargav and Dr Sharda Jain
Introduction
Social egg freezing (oocyte cryopreservation for non-medical reasons) has evolved as a proactive option for women looking to extend their reproductive possibilities past their peak childbearing years
It is the process of saving or protecting eggs, or reproductive tissues so that a person can use them to have biological children in future
White Coat Hypertension During Pregnancy : Dr Sharda JainLifecare Centre
During pregnancy, white coat hypertension has an average prevalence of 15% to 30%. While 60-70% of detected cases of white coat hypertension actually have true gestational hypertension or pre-existing essential hypertension that require monitoring and treatment. Choices of anti-hypertension medication during pregnancy need to be considered carefully.
White Coat hypertension Why it is Important? : Dr Sharda JainLifecare Centre
This document outlines an epidemiology and definitions presentation on hypertension. It discusses types of hypertension like white coat hypertension, where anxiety in a medical environment causes abnormally high readings. Isolated systolic hypertension is also covered, noting that systolic blood pressure is a more important risk factor after age 50. Statistics are provided on hypertension being a major cause of premature death worldwide and its prevalence in India. The summary concludes that white coat hypertension has a prevalence of 20-35% and is associated with minimal increased risk, though 60-70% of cases ultimately have true hypertension requiring treatment and monitoring.
Know Your Blood Pressure Understanding Blood Pressure Reading : Dr Sharda JainLifecare Centre
Hypertension, or high blood pressure, affects over a quarter of the global adult population. A blood pressure reading contains two numbers that indicate systolic and diastolic pressure. There are different types of hypertension including primary or essential hypertension and secondary hypertension caused by an underlying medical condition.
This document provides an overview of stillbirths including definitions, epidemiology, etiology, approaches to management of stillbirth cases and subsequent pregnancies. It notes that the stillbirth rate in India in 2021 was 12.4 per 1000 births. Investigating the causes of stillbirth involves examining the mother, fetus, placenta and membranes through history, examinations, tests and potentially an autopsy. Managing subsequent pregnancies after a stillbirth includes increased surveillance and optimizing any medical conditions to reduce recurrence risks. The aim is to reduce India's stillbirth rate to 10 per 1000 births by 2030.
IRON DEFICIENCY ANEMIA OVERVIEW WITH FOCUS ON PARENTRAL IRON THERAPY : Dr ...Lifecare Centre
This document provides an overview of iron deficiency anemia with a focus on parental iron therapy. Some key points:
- Iron deficiency anemia affects around 2 billion people globally and has a prevalence of 50.1% among pregnant women in India.
- Parenteral iron therapies like ferric carboxymaltose are recommended for pregnant women who are anemic late in pregnancy or those with low compliance to oral iron due to the ability to deliver a complete replacement dose in a single infusion.
- Ferric carboxymaltose has advantages over earlier parenteral iron formulations as it is a robust carbohydrate-iron complex that allows for higher dosing, has a shorter infusion time, and has a
CHECK LIST FOR ART SPECIALIST BEFORE IVF-ICSI FOR PATIENTS SEEKING IVF -ICSI ...Lifecare Centre
The document provides a checklist for an ART specialist to follow before performing IVF-ICSI treatment for patients. It outlines several areas to evaluate including conducting medical evaluations of both partners, assessing fertility through testing, providing psychological evaluation and counseling, reviewing lifestyle factors and making modifications, ensuring vaccinations are up to date, screening for infections, considering genetic testing, providing preconception care, discussing financial aspects and consent forms, explaining the ovarian stimulation and embryo transfer processes, and scheduling follow up appointments. The specialist should tailor the checklist to each patient's specific needs and circumstances and provide clear communication and support throughout the IVF-ICSI process.
CMV UPDATE Few solid facts about cytomegalovirus (CMV) Infection & New devel...Lifecare Centre
CMV UPDATE Few solid facts about cytomegalovirus (CMV) Infection & New development from France for Indian Gynaecologists & public to know :Dr Sharda Jain
CMV is a common herpesvirus that can infect people of all ages, including pregnant women.
CMV is not the same as HSV (herpes simplex virus), although they belong to the same viral family.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Kat...rightmanforbloodline
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
TEST BANK For Basic and Clinical Pharmacology, 14th Edition by Bertram G. Katzung, Verified Chapters 1 - 66, Complete Newest Version.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
3. Contents 1. Overview of Endometriosis
2. Diagnosis, Grading, And Classification
Of Endometriosis
3. Endometriosis and Infertility
4. Rationale For Management Of
Endometriosis
5. Dydrogesterone: The Right Choice For
Treatment of Endometriosis
6. Key Messages
PART - 1
5. Endometriosis: An Agonizing Condition
1. Parasar P, et al. Curr Obstet Gynecol Rep. 2017;6(1):34–41. 2. Schrager S, et al. Am Fam Physician. 2013;87(2):107–13.
Endometriosis is a chronic and recurrent disease.1,2
DEBILITATING DISEASE ,PROGRESSIVE DISEASE ,NO CURE SO FAR
The lesions can be peritoneal lesions, superficial
implants or cysts on the ovary, or deep infiltrating
lesions.1
It is characterized by functional endometrial glandular
and/or stromal lesions outside the uterus.1
6. Prevalence of Endometriosis
10% Women of reproductive age suffer from
endometriosis1
Global prevalence:
176 million women2
Prevalence in India:
25 million women3
1. Parasar P, et al. Curr Obstet Gynecol Rep. 2017;6(1):34–41. 2. Zondervan KT, et al. Nat Rev Dis Primers. 2018;4(1):9. 3. About Endometriosis – Endometriosis
Society of India. Available from: http://endosocind.org/about-endometriosis/. Accessed on: 22 July 2020.
8. Retrograde Menstruation: The Most Predominant Theory of
Endometriosis Pathogenesis
IL: interleukin; TNF: Tumour necrosis factor; RANTES: Regulated on activation, normal T expressed and secreted; VEGF: Vascular endothelial growth factor.
Macer ML, et al. Obstet Gynecol Clin North Am. 2012;39(4):535–549.
Endometrial fragments enter peritoneal cavity through fallopian tubes
Attach to peritoneal cells
Increased vascular supply
Proliferation
Endometrial
implants
Altered
immunity
IL-1, IL-6, IL-8, TNF
RANTES, VEGF
Increased
leukocytes and
macrophages in and
around endometrial
implants and in
peritoneal fluid
Cytokines and growth
factors secretion
Retrograde
menstruation
9. at the Core of Endometriosis Pathogenesis
1. Broi MGD, et al. JBRA Assist Reprod. 2019;23(3):273–280. 2. Rafique S, et al. Clin Obstet Gynecol. 2017;60(3):485.
IL: Interleukin; TNF: Tumor necrosis factor.
Endometriosis
pain and
infertility1,2
Peritoneal
endometrial
lesions1,2
Activation of
macrophages1,2
Increased generation of inflammatory
factors, reactive oxygen and nitrogen species,
proinflammatory cytokines (IL-1, IL-6, TNF-α),
growth factors, and prostaglandins1,2
Chronic inflammation,
proliferation
of lesions, and local
hormonal imbalance1,2
Adverse pelvic
environment1,2
Chronic Inflammation
11. Signs and Symptoms of Endometriosis
1. Parasar P, et al. Curr Obstet Gynecol Rep. 2017;6(1):34–41. 2. Bulletti C, et al. J Assist Reprod Genet. 2010;27(8):441–447.
Clinical
presentations of
endometriosis
Intermenstrual
bleeding1
Dysmenorrhea1
Painful intercourse1
Painful defecation1
Painful urination1
Pelvic pain1
Hemoptysis2
Menstrual cramps1
Infertility1
12. Risk Factors for Endometriosis
Peterson CM, et al. Am J Obstet Gynecol. 2013;208(6):451.
Increasing age Early menarche
Shorter menstrual
cycle interval
Prolonged
menstrual flow
Family history of
endometriosis
Low body weight
Intercourse during
menses
Caffeine intake
13. Comorbidities Associated With Endometriosis
Adenomyosis
Cancer
(e.g. endometrioid
ovarian cancer)
Autoimmune diseases
(e.g. systemic lupus
erythematosus, Sjögren
syndrome, multiple sclerosis, and
rheumatoid arthritis)
Cardiovascular conditions
(e.g. myocardial infarction,
angina, coronary angioplasty, or
stent placement)
Endometriosis-
related
comorbidities
Zondervan KT, et al. Endometriosis. Nat Rev Dis Primers. 2018;4(1):9.
14. Endometriosis Has A Negative Impact on Quality of Life
Marinho MCP, et al. J Womens Health (Larchmt). 2018;27(3):399–408.
Impaired physical,
mental, and social
well-being
Psychological
stress, anxiety,
or depression
Low self-esteem
and poor
performance at
work
Poor quality of
sleep
How does
endometriosis
impact quality
of life?
16. Diagnosis of Endometriosis
Based on clinical
history of the patient
• Uterine or adnexal
tenderness
• Retroverted fixture
• Nodulating
uterosacral ligament
• Pelvic masses
Laparoscopic inspection with histologic confirmation after
biopsy is the gold standard for diagnosis.
Parasar P, et al. Curr Obstet Gynecol Rep. 2017;6(1):34–41.
Ultrasound (pelvic,
transvaginal and
transabdominal)
MRI
CT scans
Tools to visualize
pelvic masses
CT: Computed tomography; MRI: Magnetic resonance imaging.
Preliminary diagnosis Palpate Differential diagnosis
• Urinalysis
• Pap smear
• Pregnancy test
• Vaginal and
endocervical swabs
17. Need of Early Diagnosis of Endometriosis
An average delay in diagnosis of
endometriosis in women between 18
and 45 years of age is 6.7 years.
This leads to unnecessary suffering
and reduced quality of life.
Early referral, diagnosis, identification of disease, and treatment are needed
to mitigate pain, prevent disease progression, and preserve fertility.
Non-invasive tool to diagnose endometriosis could facilitate early diagnosis
and intervention.
Parasar P, et al. Curr Obstet Gynecol Rep. 2017;6(1):34–41.
18. ASRM classification
Grading and Classification of Endometriosis (1/2)
ASRM: American Society for Reproductive Medicine.
1. Capezzuoli T, et al. Gynecol Reprod Endocrinol Metab. 2020;1(1):14–22. 2. Zondervan KT, et al. Nat Rev Dis Primers. 2018;4(1):9.
01
02
04
Stage 1 (Minimal Endometriosis)1
1–5 points
• Superficial lesions2
• Commonly on the pelvic walls or
pouch of Douglas2
Stage 2 (Mild Endometriosis) 1
6–15 points
• Superficial lesions or some deep
lesions (>5 mm infiltration below
the peritoneal surface2
Stage 3 (Moderate Endometriosis) 1
16–40 points
• Includes endometrioma and minor
adhesions between uterine and
ovarian walls2
Stage 4 (Severe Endometriosis) 1
>40 points
• Severe adhesions with bowel
and/or bladder involvement2
• Severe damage to pouch of
Douglas2
03
19. Grading and Classification of Endometriosis (2/2)
ENZIAN classification
Compartments of
retroperitoneal structures
• Compartment A: Vagina,
recto-vaginal septum
• Compartment B:
Uterosacral ligaments to
the pelvic wall
• Compartment C: Rectum
and sigmoid colon
Classification of disease
severity
• Grade 1: Invasion <1 cm
• Grade 2: Invasion 1–3 cm
• Grade 3: Invasion >3 cm
Deep endometriosis
invasion and invasion of
organs recorded
• Far adenomyosis
• Far bladder invasion
• Far intrinsic ureteral
endometriosis
• Far bowel disease cranial
to the sigmoid colon
• Other locations
Capezzuoli T, et al. Gynecol Reprod Endocrinol Metab. 2020;1(1):14–22.
21. Women with endometriosis have a lower
monthly fecundity of about 0.02–0.1 per
month.
Endometriosis is associated with a
lower live birth rate.
Infertile women are 6 to 8 times more likely to have
endometriosis than fertile women.
Endometriosis and Infertility
Bulletti C, et al. J Assist Reprod Genet. 2010;27(8):441–447.
22. Pathogenic Mechanisms in Endometriosis-
Associated Infertility
Underlying
adhesions1
Ovarian cysts1
Change in
tubal anatomy1 Abnormal
folliculogenesi
s2
Elevated
oxidative stress2
Altered immune
function2
Alteration of
follicular and
peritoneal
hormones2
Reduced
endometrial
receptivity2
1. Rafique S, et al. Clin Obstet Gynaecol. 2017;60(3):485. 2. Gupta S, et al. Fertil Steril. 2008;90(2):247–57.
23. Role of Inflammation in
Endometriosis-Associated Infertility
Macrophage
activation
Lesions in
peritoneal
endometrium
Increase in
inflammatory
factors, reactive
oxygen and nitrogen
species, cytokines,
growth factors, and
prostaglandins
Pelvic
environment
becomes
adverse
Increased
inflammation in
peritoneal fluid,
damaged oocyte,
and impaired
oocyte quality
Increased rate of
infertility in women with
endometriosis
Broi MGD, et al. JBRA Assist Reprod. 2019;23(3):273–280.
24. 03.
02.
01. Disrupts progesterone and
estrogen signaling1
Suppresses cellular response to progesterone exposure2
Hormonal imbalance leads to heightened inflammation, increased pelvic
pain, and decreased endometrial receptivity.1
PROGESTERONE RESISTANCE confers
endometrial tissue the ability to remain viable at
foreign locations through successive menstrual
cycles, as attenuation of progesterone target
genes allows for continued growth and cell
survival.2
Impaired Progesterone Signaling Exacerbates
Endometriosis Symptoms
1. Marquardt RM, et al. Int J Mol Sci. 2019;20(15):3822. 2. McKinnon B, et al. Trends Endocrinol Metab. 2018;29(8):535–48.
26. Medical Therapy Is Essential for Endometriosis
Endometriosis is impossible to cure, but it is possible to arrest the development of the
disease and alleviate the symptoms.1,2
up to 21%
up to 47%
up to 55%
0% 10% 20% 30% 40% 50% 60%
In 1 to 2
years
In 5 years
In 5 to 7
years
Recurrence rate after surgery for endometriosis3
Recurrence rate of
endometriosis is
high after surgery3
The new strategy favors conservative treatment/medical therapy, with surgery
suggested as an option only for cases that remain non-responsive for 6 months or
longer.2
1. The Ministry of Healthcare of the Russian Federation. Clinical Guidance. Endometriosis. 2016. ID: КР259. 2. Dunselman GA, et al. Hum Reprod. 2014;29(3):400–412. 3. Adamian L.
Endometriosis: Diagnostics, Treatment, and Rehabilitation. A Clinical Guide. Moscow. 2013, page 86.
27. Which Therapy Should Be Preferred for Early
Endometriosis?
Endometriosis therapy should enhance quality of life
and reproductive health 1,2
Relieve/reduce
pain symptoms3
Shrink/slow
endometrial
growths3
Preserve ovarian
reserve and treat
endometriosis
associated
infertility3,4
Prevent/delay
recurrence of the
disease3
1. The Ministry of Healthcare of the Russian Federation. Clinical Guidance. Endometriosis. 2016. ID: КР259. In Russian only. 2. Dunselman GA, et al. ESHRE guideline: management of women
with endometriosis. Hum Reprod, 2014;29(3):400–412. 3. Treatments for Endometriosis. Available at: https://endometriosisassn.org/about-endometriosis/treatments. Accessed on 22 July 2020,
Orazov MR, Radzinsky VY, Khamoshina MB, et al. The efficacy of combined management of endometriosis-associated infertility. Int J Pharm Res 2019;11(3):1001–1006
28. Recommended Hormonal Therapy for
Endometriosis Treatment
Progestogens, or
antiprogestogens
NSAIDS;
analgesics
Combined oral
contraceptives
First-line medications according to ESHRE:
Dunselman GA, et al. Hum Reprod. 2014;29(3):400–12.
ESHRE: European Society of Human Reproduction and Embryology; GnRH: Gonadotropin releasing hormone; NSAID: Non-steroidal anti-inflammatory drugs.
GnRH agonists
and
antagonists
Aromatase
inhibitors
29. Endometriosis Therapy Should Focus on Fertility
Preservation in Women Desiring Conception
Fertility Preservation in women of reproductive age
(18–40 years) should be the focus of endometriosis
therapy
Women with
endometriosis are at
risk of decreased
ovarian reserve and
ovarian tissue
damage which can
lead to:1,2
Infertility
Premature ovarian failure
Reduced response to
ovarian stimulation
1. Carrillo L, et al. J Assist Reprod Genet. 2016;33(3):317–23. 2. Llarena NC, et al. Clin Med Insights Reprod Health. 2019;13:1–8.
Although many drugs are available for endometriosis treatment, there is an unmet need for a
therapy that can preserve fertility while mitigating the endometriosis-associated pain.
32. PROGESTERONE ACTION IS CRUCIAL TO
DECREASING INFLAMMATION IN THE ENDOMETRIUM
Causes for
progesterone
resistance in the
endometrium
Repetitive retrograde endometrial
shedding exacerbates
progesterone resistance
Endometriotic lesions and surrounding
peritoneal fluid are rich in reactive oxygen
species.2
Chronic inflammation1
Oxidative stress2,3
Dydrogesterone increases
progesterone receptor
expression and decreases
proinflammatory
cytokines1
Dydrogesterone exerts
endothelial anti-
inflammatory actions via
a decrease in expression
of leukocyte adhesion
molecules.3
1. Patel BG, et al. Acta Obstet Gynecol Scand. 2017;96(6):623–32. 2. Reis FM, et al. Hum Reprod Update. 2020;26(4):565–585. 3. Chen JT, et al. J Clin Med Res. 2018;10(2):146–53.
33. Dydrogesterone Effectively Tackles Chronic
Inflammation Associated With Endometriosis
Reduces TNF-α-induced NF-κ-activation and suppresses
proliferation of endometriotic stroma cells.
Suppresses IL-8 production in lymphocytes.
Increases NO production that plays an
anti-inflammatory role.
DYD: Dydrogesterone; IL: Interleukin; NF: Nuclear factor; NO: Nitric oxide; TNF: Tumor necrosis factor.
35. Dydrogesterone Enhances Quality of Life and
Reproductive Health
Endometriosis therapy should enhance quality of life and reproductive health:
No inhibition of
ovulation2
Reduction in
pain
symptoms/ size
of
endometriosis
lesions1
Improvement
in quality of
life
parameters1
Improved
pregnancy
outcomes3
In Infertility
Patients
1. Patient Information Leaflet of Duphaston®, 06.07.2020. In Russian only. 2. . Schweppe KW. Maturitas. 2009;65:S23–7. 3. Griesinger G, et al. Reprod Biomed Online. 2019;38(2):249–59.
BCZ
Induces Atrophy
in Ectopic
Endometrial
Tissue
36. Dydrogesterone in Endometriosis: Recommended
Regimen
1. Report of the results of ORCHIDEA, a multicenter open-label observational study of dydrogesterone in the treatment of endometriosis in Russia. Data from Abbott. In Russian only.
2. Prof. A.V. Kozachenko, presentation at the 14th International Congress of Reproductive Medicine, Moscow, January 21, 2020. In Russian only.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Prolonged cyclical regimen
Continuous regimen
Dydrogesterone is the only gestagen with a choice between two efficacious
regimen for endometriosis.
Dydrogesterone
20–30 mg per day
for 6 months and
longer is the
recommended
regimen in
management of
endometriosis
37. • Endometriosis is a CHRONIC and Recurrent disease.
• DEBILITATING DISEASE ,PROGRESSIVE DISEASE
NO CURE SO FAR
• Induces atrophy in ectopic endometrial tissues
• Inhibits the formation of De- Novo endometriotic tissues without
affecting endometriosis
• Does not inhibit ovulation improves Pregnancy Rate in
Patients with infertility
• Improve the endometriosis associated pelvic pain &
quality of life (QOL)
NEW AVTAAR IOF DYDROGESTERONE IN ENDOMETRIOSIS
Editor's Notes
Welcome to today’s presentation titled, ‘Endometriosis and Infertility in Women of Reproductive Age.’
This section gives an overview of the burden and the current concepts about endometriosis.
Endometriosis, a major health problem in women during their reproductive age, is a chronic and recurrent disease.1,2 It is defined as the presence of functional endometrial glandular and/or stromal cells outside the uterine cavity. 1 The lesions can be peritoneal lesions, superficial implants or cysts on the ovary, or deep infiltrating disease.1
References
1. Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34–41.
2. Schrager S, Falleroni J, Edgoose J. Evaluation and treatment of endometriosis. Am Fam Physician. 2013;87(2):107–13.
Globally, endometriosis is known to affect about 10% of women of reproductive age,1 which translates to approximately 176 million women. According to the Endometriosis Society of India, the number of women with endometriosis is estimated to be about 25 million.3 This high prevalence rate, both globally and nationally, indicates the alarming situation and needs to draw attention from both researchers as well as physicians.
References
Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34–41.
Zondervan KT, Becker CM, Koga K, et al. Endometriosis. Nat Rev Dis Primers. 2018;4(1):9.
About Endometriosis – Endometriosis Society of India. Available from: http://endosocind.org/about-endometriosis/. Accessed on: 22 July 2020.
The definite pathogenesis of endometriosis is still unknown but there are a number of leading theories including retrograde menstruation, coelomic metaplasia, altered immunity, stem cells, and genetics.1 The most predominant theory is of retrograde menstruation. It is proposed that with retrograde menstruation the endometrial glands and stroma are attached and implanted in peritoneal cavity.2
References
Macer ML, Taylor HS. Endometriosis and infertility: A review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am. 2012;39(4):535–549.
Rafique S, Decherney AH. Medical management of endometriosis. Clin Obstet Gynecol. 2017;60(3):485.
The most well accepted theory, retrograde menstruation, states that endometrial tissue is transported in a retrograde fashion through patent fallopian tubes into the peritoneal cavity. The endometrial cells then attach to the peritoneal mesothelial cells, establish a blood supply, proliferate and produce endometrial implants. Women with endometriosis have higher volumes of refluxed menstrual blood and endometrial-tissue fragments than women without the disorder. However, the incidence of retrograde menstruation is similar in women with and without endometriosis so the pathogenesis appears to be a multi-factorial mechanism.
Women with endometriosis have altered immunity; preventing them from clearing the refluxed endometrial cells/fragments that appear in retrograde menstruation. This would help explain why some women with retrograde menstruation develop endometriosis while others do not. Cell-mediated immunity is thought to be deficient in patients with the disease; leukocytes are unable to recognize that the endometrial tissue is not in its normal location. Once endometriosis develops, the immune system has also been to shown to potentiate the development and increase the severity of the disease. In women with endometriosis there are increased numbers of leukocytes and macrophages in and around endometrial implants and in the peritoneal fluid. These cells secrete cytokines and growth factors (interleukin (IL)- 1,6 and 8, tumor necrosis factor (TNF), regulated on activation, normal T expressed and secreted (RANTES), vascular endothelial growth factor (VEGF) into the peritoneal milieu, which then recruit surrounding capillaries and leukocytes. The ultimate effect is proliferation of endometriosis implants with increased vascular supply.
Reference
Macer ML, Taylor HS. Endometriosis and infertility: A review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am. 2012;39(4):535–549.
Women with endometriosis have immunological dysfunction preventing the removal of endometrial implants and leading to tissue adhesion in the peritoneal cavity. These peritoneal endometrial lesions are responsible for the activation of macrophages, with consequent increase in the generation of inflammatory factors, reactive oxygen and nitrogen species, pro-inflammatory cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor, growth factors, and prostaglandins in the endometrial lesions. A marked inflammatory response, with exacerbation of reactive species and cytokines, makes the pelvic environment adverse that is reflected in the peritoneal fluid. These alterations may lead to chronic inflammation, proliferation of lesions, local hormonal imbalance, resulting in poor oocyte quality, poor sperm motility, embryo toxicity, and reduced endometrial receptivity. Increased production of prostaglandins along with chronic inflammation leads to pain.1,2
References
Broi MGD, Ferriani RA, Navarro PA. Ethiopathogenic mechanisms of endometriosis-related infertility. JBRA Assist Reprod. 2019;23(3):273–280.
Rafique S, Decherney AH. Medical management of endometriosis. Clin Obstet Gynecol. 2017;60(3):485.
The clinical presentation of endometriosis varies. Although 20–25% of patients of endometriosis are asymptomatic, typically, endometriosis causes pain and infertility.1 Patients often present with symptoms such as intermenstrual bleeding, painful periods (dysmenorrhea), painful intercourse (dyspareunia), painful defecation (dyschezia), painful urination (dysuria), hemoptysis, and infertility in association with 1 or more of the above.1,2 Pelvic pain may present before menstruation begins. Other symptoms indicative of endometriosis include pain and a heavy feeling in the lumbo-sacral column and/or legs; nausea, lethargy, chronic fatigue; any cyclical pain affecting other organs; hemoptysis; scapular or thoracic pain; and acute abdomen.1
References
1. Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34–41.
2. Bulletti C, Coccia ME, Battistoni S, et al. Endometriosis and infertility. J Assist Reprod Genet. 2010;27(8):441–447.
The factors increasing the risk of endometriosis include increasing age, early menarche, shorter menstrual cycle interval, prolonged menstrual flow, family history of endometriosis, low body weight, intercourse during menses, and caffeine intake.
Reference
Peterson CM, Johnstone EB, Hammoud AO, et al. Risk factors associated with endometriosis: Importance of study population for characterizing disease in the ENDO Study. Am J Obstet Gynecol. 2013;208(6):451.
Patients with endometriosis may be at a high risk of developing several other chronic diseases:
Adenomyosis: A study including 227 women with infertility showed that the prevalence of adenomyosis was reported as high as 79% among women with surgically confirmed endometriosis compared with 28% among women without endometriosis.
Cancer: Endometriosis is known to be positively associated with cancer (e.g. endometrioid ovarian cancer).
Autoimmune diseases: Patients with endometriosis show a higher risk of autoimmune diseases, such as systemic lupus erythematosus (SLE), Sjögren syndrome, multiple sclerosis, and rheumatoid arthritis.
Cardiovascular conditions: Patients with endometriosis are at a greater risk of myocardial infarction, angina, need for coronary artery bypass graft surgery, coronary angioplasty, or stent placement. Other cardiovascular disease risk factors such as hypertension and hypercholesterolemia are also associated with endometriosis.
Reference
Zondervan KT, Becker CM, Koga K, et al. Endometriosis. Nat Rev Dis Primers. 2018;4(1):9.
Endometriosis has a negative impact on the quality of life as well. The painful symptoms may significantly impair physical, mental, and social well-being; and infertility itself may cause psychological stress, low self-esteem, and depression. Improvement of quality of life should be considered an important point during the management of endometriosis.
Reference
Marinho MCP, Magalhaes TF, Fernandes LFC, et al. Quality of Life in Women with Endometriosis: An Integrative Review. J Womens Health (Larchmt). 2018;27(3):399–408.
In this section, we will discuss the methods used for the diagnosis of endometriosis and the criteria for grading and classification.
Preliminary diagnosis of endometriosis is usually based on the clinical history as the majority of women show normal results of physical examination. The clinicians palpate for uterine or adnexal tenderness, a retroverted fixture, nodulating uterosacral ligament, and any pelvic masses. A tenderness on palpation of posterior fornix is the most common finding. Differential diagnosis is important because pelvic pain is also a symptom of other diseases (such as pelvic adhesions, adenomyosis, and gastrointestinal or urologic disorders). Other causes of pelvic pain should be ruled out by carrying out appropriate diagnostic tests like urinalysis, Pap smear, pregnancy test, vaginal and endocervical swabs. Pelvic masses are visualized by the use of transvaginal and transabdominal ultrasound. Occasionally, a magnetic resonance imaging and computed tomography scans are conducted to characterize the pelvic masses. Laparoscopic inspection with histologic confirmation after biopsy is the gold standard for diagnosis.
Reference
Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34–41.
The average delay in diagnosis of endometriosis is about 6.7 years resulting in unnecessary suffering and reduced quality of life. As the majority of women with endometriosis report the onset of symptoms during adolescence, early referral, diagnosis, identification of disease, and treatment may mitigate pain, prevent disease progression, and thus preserve fertility. Barriers to early diagnosis include high cost of diagnosis and treatment in adolescent patients and presentation of confounding symptoms, such as cyclic and acyclic pain. Thus, a non-invasive tool to diagnose endometriosis could facilitate earlier diagnosis and intervention that could ultimately improve quality of life and preserve fertility.
Reference
Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34–41.
The American Society for Reproductive Medicine classification system is the most widely used classification worldwide. It considers the intraoperative disease findings, and takes into account peritoneal endometriosis, ovarian endometriosis, posterior cul-de–sac obliteration, ovarian adhesions, and tubal adhesions. Scores are assigned to endometriosis lesions in the peritoneum and ovaries using points that correspond to the size of the lesions. By analogy, points are also assigned for adhesions on the ovaries and fallopian tubes. Additional points are assigned for partial or complete posterior cul-de–sac obliteration. The assigned points are summed and a value is obtained to classify the disease based on its severity.1 Stage I (minimal, 1–5 points) usually comprises few superficial endometriotic spots or adhesions. Stage II (mild, 6–15 points) can be a few , deep peritoneal lesions solely or in combination with superficial lesions and filmy adhesions. Stage III (moderate, 16–40 points) often includes an endometrioma by itself or in combination with superficial or deep endometriosis and/or dense adhesions. Stage IV (severe, >40 points) is often characterized by all of the above as well as bilateral ovarian endometrioma and/or dense adhesions that can lead to a partial or complete obliteration of the lesser or true pelvis (the structure that contains all the pelvic organs).2
Reference
1. Capezzuoli T, Clemenza S, Sorbi F, et al. Classification/staging systems for endometriosis: The state of the art. Gynecol Reprod Endocrinol Metab. 2020;1(1):14–22.
2. Zondervan KT, Becker CM, Koga K, et al. Endometriosis. Nat Rev Dis Primers. 2018;4(1):9.
The ENZIAN classification was developed as a supplement to the American Society for Reproductive Medicine classification score, in order to provide a morphologically descriptive classification of DIE, taking into account retroperitoneal structures. The prefix ‘F’ stands for ‘far’ or ‘foreign,’ referring to distant retroperitoneal structures. The ENZIAN classification nomenclature is similar to the tumor, lymph nodes, metastasis (TLM) staging system used in cancer staging.
Reference
Capezzuoli T, Clemenza S, Sorbi F, et al. Classification/staging systems for endometriosis: The state of the art. Gynecol Reprod Endocrinol Metab. 2020;1(1):14–22.
In this section, we will discuss the relationship of endometriosis with infertility.
Endometriosis is closely linked with infertility. In normal couples, fecundity is in the range of 0.15 to 0.20 per month and decreases with age. Women with endometriosis tend to have a lower monthly fecundity of about 0.02–0.1 per month. Also, endometriosis is associated with a lower live birth rate. Infertile women are six to eight times more likely to have endometriosis than fertile women.
Reference
Bulletti C, Coccia ME, Battistoni S, et al. Endometriosis and infertility. J Assist Reprod Genet. 2010;27(8):441–447.
The pathogenic mechanisms associated with infertility in endometriosis include underlying adhesions, ovarian cyst, change in tubal anatomy,1 abnormal folliculogenesis, elevated oxidative stress, altered immune function, altered hormonal milieu in the follicular and peritoneal environment, and reduced endometrial receptivity.2
References
Rafique S, Decherney AH. Medical management of endometriosis. Clin Obstet Gynaecol. 2017;60(3):485.
Gupta S, Goldberg JM, Aziz N, Goldberg E, Krajcir N, Agarwal A. Pathogenic mechanisms in endometriosis-associated infertility. Fertil Steril. 2008;90(2):247-257.
The immune function is known to be dysregulated in endometriosis patients. Peritoneal endometrial lesions are responsible for the activation of macrophages, with consequent increase in the generation of inflammatory factors, reactive oxygen and nitrogen species, cytokines, growth factors, and prostaglandins. This makes the pelvic environment adverse, which is reflected in the peritoneal fluid of these women. These changes in the microenvironment cause oocyte damage and lead to impairment of oocyte quality in endometriosis patients.
Reference
Broi MGD, Ferriani RA, Navarro PA. Ethiopathogenic mechanisms of endometriosis-related infertility. JBRA Assist Reprod. 2019;23(3):273–280.
In endometriosis, when endometrial tissue grows outside the uterine cavity, progesterone and estrogen signaling are disrupted, commonly resulting in progesterone resistance and estrogen dominance.1 Progesterone resistance describes the suppressed cellular response to progesterone exposure.2 This hormone imbalance leads to heightened inflammation and may also increase pelvic pain and decrease endometrial receptivity to embryo implantation.1 In endometriosis, it confers endometrial tissue the ability to remain viable at foreign locations through successive menstrual cycles, as attenuation of progesterone target genes allows for continued growth and cell survival.2
References
Marquardt RM, Kim TH, Shin JH, et al. Progesterone and estrogen signaling in the endometrium: What goes wrong in endometriosis? Int J Mol Sci. 2019;20(15):3822.
McKinnon B, Mueller M, Montgomery G. Progesterone resistance in endometriosis: An acquired property? Trends Endocrinol Metab. 2018;29(8):535–48.
In this section, we will discuss the rationale behind endometriosis treatment and the new for a new therapy for fertility preservation.
Endometriosis is impossible to cure, but it is possible to arrest the development of the disease and alleviate the symptoms.1,2
Adamian et al. showed that the recurrence rate after endometriosis surgery is high, gradually increasing from 21% in 1-2 years to 55% in 5-7 years.3
Thus, a new strategy was devised that favors conservative treatment/medical therapy, with surgery suggested as an option only for cases that remain non-responsive for 6 months or longer.2
References
The Ministry of Healthcare of the Russian Federation. Clinical Guidance. Endometriosis. 2016. ID: КР259. In Russian only.
Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: Management of women with endometriosis. Hum Reprod. 2014;29(3):400–412.
Adamian L. Endometriosis: Diagnostics, Treatment, and Rehabilitation. A Clinical Guide. Moscow. 2013, page 86. In Russian only.
Medical treatment for endometriosis should prevent loss of reproductive health and enhance quality of life.1,2
Endometriosis treatment goals should include:3
Relieve/reduce pain symptoms
Shrink/slow endometrial growths
Preserve ovarian reserve and restore fertility in long-term use
Prevent/delay the recurrence of the disease
References
The Ministry of Healthcare of the Russian Federation. Clinical Guidance. Endometriosis. 2016. ID: КР259. In Russian only.
Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: Management of women with endometriosis. Hum Reprod. 2014;29(3):400–12.
Treatments for Endometriosis. Available at: https://endometriosisassn.org/about-endometriosis/treatments. Accessed on: 22 July 2020.
Currently, progestagens and anti-progestagens, non-steroidal anti-inflammatory drugs, analgesics, combined oral contraceptives, GnRH agonists and antagonists, and aromatase inhibitors are in clinical use.
With no overwhelming evidence to support particular treatments over others, it is important that the decisions involved in any treatment plan are individual, and that a woman is able to make these based on an informed choice and a good understanding of what is happening to her body.
Reference
Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: Management of women with endometriosis. Hum Reprod. 2014;29(3):400–12.
Fertility Preservation in women of reproductive age (18–40 years) should be the focus of endometriosis therapy. Women with endometriosis are at risk of decreased ovarian reserve and ovarian tissue damage that can lead to infertility, reduced response to ovarian stimulation, and premature ovarian failure.1,2
Although many drugs are available for endometriosis treatment, there is an unmet need for a therapy that can preserve fertility while mitigating the endometriosis-associated pain.
References
Carrillo L, Seidman DS, Cittadini E, et al. The role of fertility preservation in patients with endometriosis. J Assist Reprod Genet. 2016;33(3):317–23.
Llarena NC, Falcone T, Flyckt RL. Fertility preservation in women with endometriosis. Clin Med Insights Reprod Health. 2019;13:1–8.
Now let us discuss why dydrogesterone is the right choice for the treatment of endometriosis.
Now let us discuss why dydrogesterone is the right choice for the treatment of endometriosis.
Progesterone action is crucial to decreasing inflammation in the endometrium, and deviant progesterone signaling results in a proinflammatory phenotype. Conversely, chronic inflammation can induce a progesterone-resistant state. Repetitive retrograde endometrial shedding begets chronic peritoneal inflammation, which further exacerbates progesterone resistance.1 Dydrogesterone may overcome this phenomenon by increasing progesterone receptor expression and decreasing proinflammatory cytokines.1
Oxidative stress is another mechanism involved in progesterone resistance in endometriosis.2,3 The endometriotic lesions and the surrounding peritoneal fluid are rich in reactive oxygen species.2 Dydrogesterone exerts endothelial anti-inflammatory actions (i.e. via a decrease in expression of leukocyte adhesion molecules), thereby attenuating oxidative stress.3
References
Patel BG, Rudnicki M, Yu J, et al. Progesterone resistance in endometriosis: Origins, consequences and interventions. Acta Obstet Gynecol Scand. 2017;96(6):623–32.
Reis FM, Coutinho LM, Vannuccini S, et al. Progesterone receptor ligands for the treatment of endometriosis: The mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020;26(4):565–585.
Chen JT, Kotani K. Different effects of oral contraceptive and dydrogesterone treatment on oxidative stress levels in premenopausal women. J Clin Med Res. 2018;10(2):146–53.
Dydrogesterone controls the growth of endometriosis by an anti-inflammatory mechanism. Tumor necrosis factor (TNF)-α and estradiol induce the proliferation of endometriotic stroma cells via nuclear factor (NF)-kappa-β, whereas dydrogesterone reduces TNF-α-induced NF-kappa-β activation. Interleukin (IL)-8 is one of the most potent angiogenic factors. Dydrogesterone also modulates immune responses via suppression of IL-8 production in lymphocytes. The increase in nitric oxide production seen with dydrogesterone also plays an important anti-inflammatory role.
Reference
Schweppe KW. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas. 2009;65:S23–7.
Dydrogesterone enhances the quality of life and reproductive health as it leads to improvement of various endometriosis-related problems. It helps in:
Reduction in pain symptoms/ size of endometriosis lesions1
Improvement in quality of life parameters1
No inhibition of ovulation2
Improved pregnancy outcomes3
References
Patient Information Leaflet of Duphaston®, 06.07.2020. In Russian only.
Schweppe KW. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas. 2009;65:S23–7.
Griesinger G, Tournaye H, Macklon N, et al. Dydrogesterone: Pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019;38(2):249–59.
The study showed that dydrogesterone 20-30 mg per day, either cyclical or continuous regimen for 6 months and longer is the only gestagen for a doctor to have a choice between two efficacious regimens for endometriosis.
References
1. Report of the results of ORCHIDEA, a multicenter open-label observational study of dydrogesterone in the treatment of endometriosis in Russia. Data from Abbott. In Russian only.
2. Prof. A.V. Kozachenko, presentation at the 14th International Congress of Reproductive Medicine, Moscow, January 21, 2020. In Russian only.